[
  {
    "ts": null,
    "headline": "Why Eli Lilly and Company (LLY) Is The Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom",
    "summary": "We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivizes Pharmaceuticals to Build Domestic […]",
    "url": "https://finnhub.io/api/news?id=b3d04b640c2f200ed1dc7a60472f8ce9890b7ebc782652792fcc84bde0519784",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747170567,
      "headline": "Why Eli Lilly and Company (LLY) Is The Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom",
      "id": 134460717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivizes Pharmaceuticals to Build Domestic […]",
      "url": "https://finnhub.io/api/news?id=b3d04b640c2f200ed1dc7a60472f8ce9890b7ebc782652792fcc84bde0519784"
    }
  },
  {
    "ts": null,
    "headline": "Trump's EO Targets Big Pharma Stocks like Eli Lilly",
    "summary": "Trump's order looking to cut prescription drug prices is bearish for drug stocks at the surface, but is the worst already priced in?",
    "url": "https://finnhub.io/api/news?id=1b0ab619da5a69901f9d98537a38399b5c2fcd154b75d4d8c9eef7e6b27f7d6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747168560,
      "headline": "Trump's EO Targets Big Pharma Stocks like Eli Lilly",
      "id": 134460718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump's order looking to cut prescription drug prices is bearish for drug stocks at the surface, but is the worst already priced in?",
      "url": "https://finnhub.io/api/news?id=1b0ab619da5a69901f9d98537a38399b5c2fcd154b75d4d8c9eef7e6b27f7d6c"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...",
    "summary": "Sangamo Therapeutics Inc (SGMO) reports significant milestones and strategic initiatives, despite financial challenges, in its Q1 2025 earnings call.",
    "url": "https://finnhub.io/api/news?id=623a102b227743d12e1107d79672b09eb55f0f12379c60dfc77cbf5b3ae46220",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747155661,
      "headline": "Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...",
      "id": 134408460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sangamo Therapeutics Inc (SGMO) reports significant milestones and strategic initiatives, despite financial challenges, in its Q1 2025 earnings call.",
      "url": "https://finnhub.io/api/news?id=623a102b227743d12e1107d79672b09eb55f0f12379c60dfc77cbf5b3ae46220"
    }
  },
  {
    "ts": null,
    "headline": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=a28081e22173114cd938b566a5a3e1fc156f30aff03d0735d71337463e1616d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747150810,
      "headline": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "id": 134408462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=a28081e22173114cd938b566a5a3e1fc156f30aff03d0735d71337463e1616d4"
    }
  },
  {
    "ts": null,
    "headline": "Quality Growth Stocks Make Sense for an Uncertain Economy",
    "summary": "Quality Growth Stocks Make Sense for an Uncertain Economy",
    "url": "https://finnhub.io/api/news?id=ea8fd45743324f6fc2e69daf9efca385312427f731ee10657986b5ad56e80e20",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747150080,
      "headline": "Quality Growth Stocks Make Sense for an Uncertain Economy",
      "id": 134437228,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Quality Growth Stocks Make Sense for an Uncertain Economy",
      "url": "https://finnhub.io/api/news?id=ea8fd45743324f6fc2e69daf9efca385312427f731ee10657986b5ad56e80e20"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump’s Executive Order.",
    "summary": "There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.",
    "url": "https://finnhub.io/api/news?id=d33f465d744d98c002ff8009fcd14dd04cfb9c137a090ae62554c09b8767bd39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747149480,
      "headline": "Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump’s Executive Order.",
      "id": 134408464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.",
      "url": "https://finnhub.io/api/news?id=d33f465d744d98c002ff8009fcd14dd04cfb9c137a090ae62554c09b8767bd39"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen",
    "summary": "J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=320533a4eecb703b72d1f8b25b1eb735bf445b2d520cb9cffb5d6909392ca080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747142520,
      "headline": "The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen",
      "id": 134408465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=320533a4eecb703b72d1f8b25b1eb735bf445b2d520cb9cffb5d6909392ca080"
    }
  },
  {
    "ts": null,
    "headline": "Why Lilly (LLY) International Revenue Trends Deserve Your Attention",
    "summary": "Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.",
    "url": "https://finnhub.io/api/news?id=ec4db230623287f62a6237d3649a28392444c0ac9fe9f6faa613e3880b439063",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747142182,
      "headline": "Why Lilly (LLY) International Revenue Trends Deserve Your Attention",
      "id": 134408466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.",
      "url": "https://finnhub.io/api/news?id=ec4db230623287f62a6237d3649a28392444c0ac9fe9f6faa613e3880b439063"
    }
  },
  {
    "ts": null,
    "headline": "How Hims & Hers survived the great Spac shakeout",
    "summary": "About five years ago, special purpose acquisition companies — or Spacs — were all the rage in the US. Start-ups light years away from profitability...",
    "url": "https://finnhub.io/api/news?id=6d3abb465fe341af2fbcee8ec60f72f0a113516615fe0478ab7c8037f211e75f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747140365,
      "headline": "How Hims & Hers survived the great Spac shakeout",
      "id": 134408467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "About five years ago, special purpose acquisition companies — or Spacs — were all the rage in the US. Start-ups light years away from profitability...",
      "url": "https://finnhub.io/api/news?id=6d3abb465fe341af2fbcee8ec60f72f0a113516615fe0478ab7c8037f211e75f"
    }
  },
  {
    "ts": null,
    "headline": "RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US",
    "summary": "Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.",
    "url": "https://finnhub.io/api/news?id=42cf036c51e4f664d10e747b15cee0731517aa58edac54b6a1e67129b851754b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747138860,
      "headline": "RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US",
      "id": 134408469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.",
      "url": "https://finnhub.io/api/news?id=42cf036c51e4f664d10e747b15cee0731517aa58edac54b6a1e67129b851754b"
    }
  },
  {
    "ts": null,
    "headline": "Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared",
    "summary": "President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.",
    "url": "https://finnhub.io/api/news?id=23bbeb15ae0717dfdb51c6a7609af3434ba7986e390b2ba72908dbe1393246e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747136160,
      "headline": "Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared",
      "id": 134408470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.",
      "url": "https://finnhub.io/api/news?id=23bbeb15ae0717dfdb51c6a7609af3434ba7986e390b2ba72908dbe1393246e1"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Global Fund Q1 2025 Commentary",
    "summary": "Class A shares outperformed the MSCI ACWI Growth Index and ranked in the 78th percentile of the Morningstar Global Large Stock Growth category for the first quarter.",
    "url": "https://finnhub.io/api/news?id=6fa047ab330af152e655396692dc08c48a87ffe27c35a8a8a14e18476d85008e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747132200,
      "headline": "Invesco Global Fund Q1 2025 Commentary",
      "id": 134400059,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303046106/image_1303046106.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Class A shares outperformed the MSCI ACWI Growth Index and ranked in the 78th percentile of the Morningstar Global Large Stock Growth category for the first quarter.",
      "url": "https://finnhub.io/api/news?id=6fa047ab330af152e655396692dc08c48a87ffe27c35a8a8a14e18476d85008e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?",
    "summary": "Eli Lilly trades at $759 per share and has stayed right on track with the overall market, losing 6.5% over the last six months while the S&P 500 is down 2.4%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=8b2fb5ec2845b905ab5c3cb0753e30fc82e3af3db0662b5ed920189a81ab8d4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747108929,
      "headline": "Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?",
      "id": 134408472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly trades at $759 per share and has stayed right on track with the overall market, losing 6.5% over the last six months while the S&P 500 is down 2.4%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=8b2fb5ec2845b905ab5c3cb0753e30fc82e3af3db0662b5ed920189a81ab8d4e"
    }
  }
]